|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | ***Side effect*** | **PO (%)** | **IV (%)** | **IT (%)** | **Combination (%)** |
| ***Systemic*** | Hyperglycemia | 2.1-29.8 | 11.9-48.0 |  | 23.1 |
|  | Hypertension | 4.2-37.9 | 4.3 |  | 13.5 |
|  | Gastric disturbance | 4.2-27.9 | 2.2-21.4 |  | 48.1 |
|  | Mood or sleep disturbance | 2.3-44.6 | 16.1-41.3 |  | 73.1 |
|  | | | | | |
| ***Local*** | Otalgia |  |  | 6.1-54.3 | 3.8-13.5 |
|  | Dizziness |  |  | 5.5-27.1 | 8.1-28.3 |
|  | Transient perf. |  |  | 1.3-4.7 | 5.4 |
|  | Persistent perf. |  |  | 3.9-11.5 | 4.0 |
|  | Infection |  |  | 4.7 | 2.2 |

*Table 13: Summary of adverse events grouped by route of administration.*